U-Turn: NICE Recommends Rituximab, Humira In Arthritis Indications After Second Review
This article was originally published in The Pink Sheet Daily
U.K. agency reverses unfavorable preliminary opinions based on submissions from Roche and Abbott.
You may also be interested in...
Economic austerity and the resulting pressure on health care spend leaves little room for maneuver among Europe’s health technology assessment agencies.
U.K. agency’s preliminary appraisal on cost effectiveness does not call for recommending adalimumab.
The agency, however, recommends use of Abbott's Humira, Wyeth's Enbrel and Johnson & Johnson's Remicade to treat RA.